Clinical Trial Update: Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020). [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy, safety, and pharmacokinetics of sugammadex at three time points after 0.6 mg/kg Esmeron in male participants; completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromuscular Blockade

Drugs mentioned

• Esmeron (rocuronium)
• Sugammadex (sugammadex)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neuromuscular Blockade | Phase 2 | Status: COMPLETED | Results posted: 2019-02-01